Target intelligence / Profile preview

Trypanosome purine transporter system (ENT)

Target
ENT
Molecular classification
Transporter, Equilibrative nucleoside transporter family
01

Overview

The Trypanosome purine transporter system is a critical survival mechanism for protozoan parasites of the genus Trypanosoma, which are auxotrophic for purines and cannot synthesize them de novo [Landfear, 2004]. These parasites rely entirely on salvaging purines from the host's environment using specialized transporters, primarily categorized into P1 and P2 types [Mäser, 1999]. The P2 transporter, encoded by the TbAT1 gene in Trypanosoma brucei, is particularly significant as it facilitates the high-affinity uptake of adenosine and adenine [Geiser, 2005]. Beyond its physiological role, the P2 transporter serves as the primary route of entry for several essential trypanocidal drugs, including melarsoprol and pentamidine [Barrett, 2007]. Mutations or deletions in these transporter genes are major drivers of drug resistance in clinical settings, as the parasite can survive by relying on alternative salvage pathways while excluding the toxins [Matovu, 2003]. The P1 transporters, by contrast, handle a broader range of substrates including inosine, guanosine, and hypoxanthine, ensuring metabolic flexibility [De Koning, 2001]. Understanding the substrate specificity and kinetics of these transporters is vital for developing next-generation nucleoside analogs that can bypass resistance mechanisms [Berg, 2010]. This system represents a classic example of how metabolic dependencies in pathogens can be exploited for targeted drug delivery [Fairlamb, 2003].

Other names
P1 transporterP2 transporterTbAT1Equilibrative nucleoside transporterPurine permeaseAdenosine transporterNucleoside transporter
02

Mechanism of action

Facilitated diffusion of purine nucleosides and nucleobases; selective uptake of trypanocidal drugs into the parasite cytoplasm via high-affinity transport proteins.

03

Biological functions

Purine salvageNucleoside transportNutrient uptakeMetabolic homeostasis
04

Disease associations

African trypanosomiasisChagas diseaseInfection
05

Safety considerations

Development of clinical drug resistance due to transporter lossCross-resistance between arsenical and diamidine drugsPotential for treatment failure in patients with mutant parasite strains
06

Interacting drugs

Melarsoprol

4 more in the full profile.

07

Biomarkers

TbAT1 gene deletionTbAT1 point mutationsLoss of HAPT1 (High-affinity pentamidine transporter) activity

Beyond the preview

Go deeper on Trypanosome purine transporter system (ENT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trypanosome purine transporter system (ENT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call